T1	Participants 45 100	patients with non-ST elevation acute coronary syndromes
T2	Participants 187 239	non-ST elevation acute coronary syndromes (NSTE ACS)
T3	Participants 353 771	26,466 NSTE ACS patients from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb), Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) A and B trials to ascertain the timing of adverse events
T4	Participants 925 974	patients into low-, medium-, and high-risk groups
T5	Participants 1683 1717	substantial proportion of patients
T6	Participants 1908 1974	evidence-based therapies to improve the outcomes of these patients
